LEXXW News and Press, Lexaria Bioscience Corp. Warrant From 01/27/22

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today provided an annual letter from CEO Chris Bunka and a thorough strategic update to all stakeholders. In the update, Bunka described Lexaria’s key area of focus to improve the company’...

KELOWNA, BC / ACCESSWIRE / January 27, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide an annual letter from CEO, Chris Bunka and a thorough strategic update to all stakeholders. ...

(TheNewswire) “Cannabinoids have the potential to prevent as well as treat infection by SARS-CoV-2 ” Kelowna, British Columbia – TheNewswire - January 18, 202 2 – Lexaria Bioscience Corp. (Nasdaq:L...

• Dosing is expected to begin by April, 2022 KELOWNA, BC / ACCESSWIRE / December 29, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the " Company " or " Lexaria "), a global innovator in drug delivery platforms, is pleased to report that Independent Review Board ("I...

KELOWNA, BC / ACCESSWIRE / December 16, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the " Company " or " Lexaria "), a global innovator in drug delivery platforms announces that it has entered into an advertising and media agreement (the " Contract ") for media buys and digi...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced that its human clinical study HYPER-H21-3 is expected to complete all dosing and sample collection this week. The study, undertaken to examine the effects of DehydraTECH-CBD upon acute ...

(TheNewswire) Kelowna, British Columbia – TheNewswire - December 14, 2021 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platfor...

(TheNewswire) Results suggest broader applications for DehydraTECH-CBD beyond hypertension Kelowna, British Columbia - TheNewswire - December 8, 2021 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company...

Results suggest broader applications for DehydraTECH-CBD beyond hypertension KELOWNA, BC / ACCESSWIRE / December 8, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to issue follow-up resul...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced its plans for several new and ongoing DehydraTECH(TM)-applied R&D programs for 2022. According to the update, the studies mentioned in the announcement represent only a fraction of ...